Home The Word Brain | My Amedeo FAQ Privacy About | ||||||||||
The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al. |
Leukemia |
Free Subscription
2 Acta Haematol |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Leukemia is free of charge.
Efficacy of preexposure prophylaxis with monoclonal-antibody
tixagevimab-cilgavimab against emerging SARS-CoV-2 resistant variants in patients
with chronic lymphocytic leukemia.
Acta Haematol. 2024 Mar 12. doi: 10.1159/000537690.
PubMed
Abstract available
The effect of mind-body intervention on lymphocyte doubling time and treatment
free survival in treatment-naive chronic lymphocytic leukemia patients.
Acta Haematol. 2024 Mar 8. doi: 10.1159/000538055.
PubMed
Abstract available
A new chemotherapy-free regimen of olverembatinib in combination with venetoclax
and dexamethasone for newly diagnosed Ph+ acute lymphoblastic leukemia:
Preliminary outcomes of a prospective study.
Am J Hematol. 2024 Mar 14. doi: 10.1002/ajh.27289.
PubMed
Successful treatment of a B/T MPAL patient by chemo-free treatment with
venetoclax, azacitidine, and blinatumomab.
Ann Hematol. 2024;103:1397-1402.
PubMed
Abstract available
Decitabine-containing conditioning improved outcomes for children with
higher-risk myelodysplastic syndrome undergoing allogeneic hematopoietic stem
cell transplantation.
Ann Hematol. 2024;103:1345-1351.
PubMed
Abstract available
Flow cytometry-based measurable residual disease (MRD) analysis identifies AML
patients who may benefit from allogeneic hematopoietic stem cell transplantation.
Ann Hematol. 2024;103:1187-1196.
PubMed
Abstract available
Red cell exchange for rapid leukoreduction in adults with hyperleukocytosis and
leukostasis.
Blood. 2024;143:1049-1054.
PubMed
Abstract available
Identification and surveillance of rare relapse-initiating stem cells during
complete remission post-transplantation.
Blood. 2023 Dec 14:blood.2023022851. doi: 10.1182/blood.2023022851.
PubMed
Abstract available
How I manage acute respiratory failure in patients with hematological
malignancies.
Blood. 2024;143:971-982.
PubMed
Abstract available
Integrated analysis of transcriptome and genome variations in pediatric T cell
acute lymphoblastic leukemia: data from north Indian tertiary care center.
BMC Cancer. 2024;24:325.
PubMed
Abstract available
FLI1 induces erythroleukemia through opposing effects on UBASH3A and UBASH3B
expression.
BMC Cancer. 2024;24:326.
PubMed
Abstract available
Allogeneic haematopoietic cell transplantation for therapy-related myeloid
neoplasms arising following treatment for lymphoma: a retrospective study on
behalf of the Chronic Malignancies Working Party of the EBMT.
Bone Marrow Transplant. 2024 Jan 9. doi: 10.1038/s41409-023-02193.
PubMed
Abstract available
Role of allogeneic hematopoietic stem cell transplantation in patients with
high-risk T-cell lymphoblastic leukaemia/lymphoma: an analysis of clinical
outcomes.
Bone Marrow Transplant. 2023 Dec 23. doi: 10.1038/s41409-023-02182.
PubMed
Gilteritinib-based combination therapy in adult relapsed/refractory FLT3-mutated
acute myeloid leukaemia.
Br J Haematol. 2024;204:861-870.
PubMed
Abstract available
Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International
Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic
leukaemia after failure to hypomethylating agents.
Br J Haematol. 2024;204:898-909.
PubMed
Abstract available
Survival outcomes in patients with acute myeloid leukaemia who received
subsequent therapy for relapse in QUAZAR AML-001.
Br J Haematol. 2024;204:877-886.
PubMed
Abstract available
Single-cell RNA-seq reveals the links between the metabolic heterogeneity and
cell identity in NBM and AML.
Br J Haematol. 2024;204:1100-1104.
PubMed
Characteristics and long-term outcome in a large series of chronic myelomonocytic
leukaemia patients including 104 formerly referred to as oligomonocytic.
Br J Haematol. 2024;204:892-897.
PubMed
Abstract available
A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus
single-agent low-dose cytosine arabinoside in older patients with acute myeloid
leukaemia: Results from the LI-1 trial.
Br J Haematol. 2024;204:871-876.
PubMed
Abstract available
Distinct karyotypic and mutational landscape in trisomy AML.
Br J Haematol. 2024;204:939-944.
PubMed
Abstract available
Should oligomonocytic CMML be classified as an independent disease entity?
Br J Haematol. 2024;204:749-750.
PubMed
Abstract available
Mortality trends of chronic lymphocytic leukaemia in the United States with the
emergence of targeted therapy.
Br J Haematol. 2024;204:1114-1117.
PubMed
Tri-ing to decipher trisomy AML.
Br J Haematol. 2024;204:751-752.
PubMed
Abstract available
CSF3R P733T is a deleterious germline variant in acute leukaemia showing
gain-of-function-like T618I mutation.
Br J Haematol. 2024;204:e31-e33.
PubMed
Promoter-centred chromatin interactions associated with EVI1 expression in
EVI1+3q- myeloid leukaemia cells.
Br J Haematol. 2024;204:945-958.
PubMed
Abstract available
Venetoclax plus a hypomethylating agent versus cytarabine, aclarubicin, and
granulocyte colony-stimulating factor chemotherapy as a first-line therapy for
newly diagnosed acute myeloid leukemia: A propensity score-matched analysis.
Cancer. 2024 Mar 12. doi: 10.1002/cncr.35278.
PubMed
Abstract available
Induction of IFIT1/IFIT3 and inhibition of Bcl-2 orchestrate the treatment of
myeloma and leukemia via pyroptosis.
Cancer Lett. 2024 Mar 8:216797. doi: 10.1016/j.canlet.2024.216797.
PubMed
Abstract available
Acquired immune resistance is associated with interferon signature and modulation
of KLF6/c-MYB transcription factors in myeloid leukemia.
Eur J Immunol. 2024 Mar 11:e2350717. doi: 10.1002/eji.202350717.
PubMed
Abstract available
JSH practical guidelines for hematological malignancies, 2023: I. Leukemia-1.
Acute myeloid leukemia (AML).
Int J Hematol. 2024 Mar 14. doi: 10.1007/s12185-024-03730.
PubMed
Analysis of overweight/obese pediatric patients with acute myeloid leukemia: a
report from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 study.
Int J Hematol. 2024 Mar 9. doi: 10.1007/s12185-024-03745.
PubMed
Abstract available
European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid
Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free
Remission.
J Clin Oncol. 2024 Mar 12:JCO2301647. doi: 10.1200/JCO.23.01647.
PubMed
Abstract available
Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With
Internal Tandem Duplication Mutation of FLT3.
J Clin Oncol. 2024 Mar 12:JCO2302474. doi: 10.1200/JCO.23.02474.
PubMed
Abstract available
Chronic Lymphocytic Leukemia-Time to Care for the Survivors.
J Clin Oncol. 2024 Mar 15:JCO2302738. doi: 10.1200/JCO.23.02738.
PubMed
Correction for Gupta et al., "Bromo- and Extraterminal Domain Chromatin
Regulators Serve as Cofactors for Murine Leukemia Virus Integration".
J Virol. 2024 Mar 13:e0013524. doi: 10.1128/jvi.00135.
PubMed
Comparison of valganciclovir versus foscarnet for the treatment of
cytomegalovirus viremia in adult acute leukemia patients after allogeneic
hematopoietic cell transplantation.
Leuk Lymphoma. 2024 Mar 12:1-9. doi: 10.1080/10428194.2024.2321322.
PubMed
Abstract available
Efficacy and safety of mitoxantrone, etoposide, and cytarabine for treatment of
relapsed or refractory acute myeloid leukemia.
Leuk Res. 2024;139:107468.
PubMed
Abstract available
Addition of single dose gemtuzumab ozogamicin to intensive induction chemotherapy
in core-binding factor acute myeloid leukemia.
Leuk Res. 2024;139:107467.
PubMed
Abstract available
Clinical features and management of germline CEBPA-mutated carriers.
Leuk Res. 2024;138:107453.
PubMed
Abstract available
A critical evaluation of the EFS endpoint in AML: Does induction treatment
failure timing have a profound impact on study design and results?
Leuk Res. 2024;138:107465.
PubMed
Abstract available
NFKBIE mutations are selected by the tumor microenvironment and contribute to
immune escape in chronic lymphocytic leukemia.
Leukemia. 2024 Mar 15. doi: 10.1038/s41375-024-02224.
PubMed
Abstract available
Why are not all eligible chronic myeloid leukemia patients willing to attempt
tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to
the TKI stopping trial HALF.
Leukemia. 2024 Mar 12. doi: 10.1038/s41375-024-02215.
PubMed
Mutation order in acute myeloid leukemia identifies uncommon patterns of
evolution and illuminates phenotypic heterogeneity.
Leukemia. 2024 Mar 11. doi: 10.1038/s41375-024-02211.
PubMed
Abstract available
Correction: Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in
acute myeloid leukemia.
Leukemia. 2024 Mar 8. doi: 10.1038/s41375-024-02202.
PubMed
[Retracted] Tanshinone IIA enhances the inhibitory effect of imatinib on
proliferation and motility of acute leukemia cell line TIB?152 in vivo and
in vitro by inhibiting the PI3K/AKT/mTOR signaling pathway.
Oncol Rep. 2024;51:66.
PubMed
Abstract available
CLEC11A methylation is correlated to AML subtypes and cytogenetic risk factors
but not patient demographics.
PLoS One. 2024;19:e0300477.
PubMed
Abstract available
Thank you for your interest in scientific medicine.